Effects of intragastric administration of L-leucine, L-isoleucine and L-valine on gastric emptying, gut hormone release and blood glucose in healthy, lean volunteers.

Not Applicable

Completed

• Conditions: Obesity; Diabetes; Diet and Nutrition - Obesity; Metabolic and Endocrine - Diabetes; Oral and Gastrointestinal - Normal oral and gastrointestinal development and function

• Registration Number: ACTRN12619000718145
• Lead Sponsor: Christine Feinle-Bisset

Brief Summary

Our study shows that both leucine and isoleucine when administered intragastrically, at the dose of 10 g, lower postprandial blood glucose in healthy individuals, by reducing the early (i.e. during the first 30 min) response to a mixed-nutrient drink, while valine had no effect. While C-peptide increased in response to the drink in all four study conditions, with no differences amongst them, the greater effect of leucine was only apparent in the second postprandial hour. Valine and, to a lesser extent, isoleucine, but not leucine, stimulated glucagon before the drink, with no further effect after consumption of the drink. Leucine and valine, but not isoleucine, significantly slowed overall gastric emptying, and there was a trend for all amino acids to slow early gastric emptying.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-13
• Study Completion: 2019-12-25
• Last Update Posted: 16 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

A total of 16 healthy, lean (BMI 19-25 kg/m2) male subjects, aged between 18 - 55 years will be included. Subjects will be required to be weight stable (ie <5% fluctuation) at study entry, which will be ascertained by a stable body weight in the preceding 4 weeks.

Exclusion Criteria

Significant gastrointestinal symptoms, disease or surgery;
Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, gastrointestinal function, body weight or appetite (eg domperidone and cisapride, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)
Lactose intolerance/other food allergy(ies)
Current gallbladder or pancreatic disease
Cardiovascular or respiratory diseases
Those with low ferritin levels (less than 30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study
Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above)
High performance athletes
Current intake of greater than 2 standard drinks on greater than 5 days per week
Current smokers of cigarettes/cigars/marijuana
Current intake of any illicit substance
Vegetarians
Inability to comprehend study protocol
Restrained eaters (score >12 on the three factor eating questionnaire)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma glucose response to the mixed nutrient Resource Plus drink. [Plasma glucose will be assessed from blood samples taken at t = -31, -20, -10, -1, 15, 30, 45, 60, 90, 120 min, where t = -31 is just prior to the time of the bolus administration and t = -1 is just prior to nutrient drink consumption.]